ABSTRACT
Heavily pretreated ovarian cancer patients become progressively chemoresistant, and thereafter, only scant treatments potentially accord reasonable, albeit limited clinical efficacy. We describe a case involving a 67-year-old ovarian cancer patient who underwent multiple lines of chemotherapy and presented with recurrent disease and a CA-125 of 4112 U/mL. Thenceforth, she was treated with GL-ONC1 oncolytic viral therapy that was administered laparoscopically in accordance with a clinical trial. The patient subsequently received chemotherapy and during the fourth cycle, her CA-125 decreased to 99 U/mL; moreover, a computed tomography scan of the pelvis exhibited significant disease reduction. Viral therapy hypothetically confers significant promise in the treatment of recurrent ovarian cancer, especially in patients who remain unresponsive to traditional medications.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cystadenocarcinoma, Serous/therapy , Oncolytic Virotherapy/methods , Ovarian Neoplasms/therapy , Vaccinia virus , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , CA-125 Antigen/blood , Cystadenocarcinoma, Serous/diagnostic imaging , Cystadenocarcinoma, Serous/pathology , Drug Resistance, Neoplasm , Female , Humans , Laparoscopy , Neoplasm Recurrence, Local , Ovarian Neoplasms/diagnostic imaging , Ovarian Neoplasms/pathology , Pleural Effusion/etiology , Tomography, X-Ray ComputedABSTRACT
The Administrative Data Research Facilities (ADRF) Network is a new U.S.-based effort aimed at advancing the uses of administrative data in social science research. Together with Georgetown University's Massive Data Institute, the ADRF Network hosted its first conference in November 2017 to share approaches and build collaborative opportunities. The conference illustrated the importance of private sector data, the need for data intermediaries, and the essential process of building trust in moving forward this emerging field in the United States.
